Welcome to our dedicated page for Lexaria Bioscien news (Ticker: LEXXW), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscien stock.
Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) regularly issues news updates that focus on the development and evaluation of its patented DehydraTECH™ oral drug delivery platform. Company press releases highlight progress in human and animal studies, capital raising activities, strategic partnerships, and expansion of its intellectual property portfolio. For followers of LEXXW, this news flow offers insight into how DehydraTECH is being tested and positioned within the pharmaceutical landscape.
A major theme in Lexaria’s recent news is its work with GLP‑1 drugs such as semaglutide, tirzepatide, and liraglutide. The company reports results from multiple human pilot studies and a Phase 1b study in Australia (GLP‑1‑H24‑4), where DehydraTECH‑processed oral formulations are compared against established injectable or oral products. These releases detail safety and tolerability outcomes, reductions in total and gastrointestinal adverse events, and comparative performance on measures like HbA1c, body weight, body composition, and pharmacokinetics.
News items also cover exploratory findings with DehydraTECH‑CBD, including reported blood pressure reductions in a clinical study arm, and pre-clinical work such as a fluorescently tagged semaglutide rodent biodistribution study. Beyond R&D, Lexaria’s announcements describe registered direct offerings on Nasdaq, concurrent warrant placements, and the intended use of proceeds to fund research, working capital, and general corporate purposes.
Additional updates include the extension of a Material Transfer Agreement with a pharmaceutical company to evaluate DehydraTECH, the engagement of a global life science business development advisory firm, and the issuance of new patents in areas such as diabetes, epilepsy, and antiviral treatments. Investors and observers monitoring LEXXW news can use these releases to track Lexaria’s clinical progress, partnering discussions, financing activities, and the evolution of its DehydraTECH-focused strategy over time.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced favorable results from its first animal study and the initiation of its first human clinical study as part of its 2021 Hypertension R&D program. CEO Chris Bunka will present at the Benzinga Global Small Cap Conference on May 13, 2021, at 3:50 p.m. ET. The presentation will cover Lexaria's DehydraTECH™ drug delivery technology and its effectiveness in enhancing the delivery of cannabidiol (CBD) for hypertension and other applications. The event aims to connect small-cap companies with investors.
Lexaria Bioscience Corp. (NASDAQ:LEXX, NASDAQ:LEXXW) announced successful results from its 2021 study HYPER-A21-1, showcasing its DehydraTECH 2.0 formulations. These new formulations delivered up to 2,178% more CBD into the bloodstream and 1,737% more into brain tissue compared to a standard MCT oil control. The study involved ten rats receiving a 25 mg/Kg dose of CBD over 120 minutes. CEO Chris Bunka emphasized the substantial absorption efficiency of these formulations, which are anticipated to have applications in both pharmaceutical and consumer product markets.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) has launched its human clinical hypertension study HYPER-H21-1, examining the effectiveness of its patented DehydraTECH CBD formulation in controlling blood pressure. The study involves 24 volunteers and aims to complete dosing within weeks, with preliminary results expected by July. Secondary objectives include assessing the absorption rate of CBD and related metabolites. Lexaria has 18 granted patents and anticipates further studies to support DehydraTECH's validity as a hypertension treatment. Final results are scheduled for early September 2021.
Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) announces the appointment of Gregory Downey as the new Chief Financial Officer effective April 15, 2021. Downey, previously the Company's Controller, brings over ten years of CFO experience and will be compensated with a CDN$144,000 annual salary, a 10% increase, and stock options. The Company also plans to issue 300,000 share purchase warrants to third-party consultants, exercisable until April 16, 2024, at US$9.00 per share. Lexaria continues to advance its DehydraTECH technology for improved drug delivery.
Lexaria Bioscience Corp. (NASDAQ:LEXX) announced that its client Amari Corp.'s "Everyday Calm" CBD product was recognized as a Top CBD Product Pick by New Hope Network during the Natural Products Expo 2020. This accolade underscores the effectiveness of Lexaria's DehydraTECH technology, which enhances CBD delivery for improved consumer satisfaction. The DehydraTECH platform demonstrates a potential increase in bio-absorption by up to 10x, essential for the growth of CBD products in retail. Lexaria aims to expand the reach of its technology across multiple product formats.
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) announced its largest-ever R&D initiative for 2021, targeting four drug markets with a potential value of $87 billion. The studies will focus on enhancing delivery systems for NSAIDs, THC, nicotine, and sildenafil using the DehydraTECH technology. Key market insights include the NSAID market expected to grow to $24.4 billion by 2027 and the cannabis market projected at $40.6 billion by 2024. These initiatives aim to improve drug absorption and speed, with test articles scheduled for manufacturing and dosing in the coming months.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced successful stability testing for its DehydraTECHTM CBD-infused beverages, revealing a remarkable 93.4% potency retention one year post-production. This ensures excellent microbial purity and consistent CBD distribution without physical mixing, addressing common beverage degradation challenges. The technology, which significantly enhances cannabinoid absorption, is poised for broader applications, and Lexaria continues its industry leadership in innovative drug delivery systems.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) is advancing its hypertension research and development program, which includes three human clinical studies and two animal studies, alongside two antiviral drug evaluations. CEO Chris Bunka will present at the Benzinga Biotech Small Cap Conference on March 24, 2021, at 9:45 AM ET, detailing the company's DehydraTECH drug delivery technology aimed at improving the bio-absorption of active pharmaceutical ingredients. Lexaria holds 18 granted patents and approximately 60 pending, positioning itself strongly in the biotech sector.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) reports progress in two of four planned antiviral studies using its DehydraTECH™ technology targeting SARS-CoV-2. The studies assess the effectiveness of enhanced formulations of antiviral drugs, including Remdesivir, in animal and human cell cultures. Results from the animal study (VIRAL-A20-2) are expected by late May, while human cell evaluations (VIRAL-C21-3) will commence in April, with results anticipated in June. The entire research initiative is fully funded and aims for regulatory approvals and commercial partnerships.
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) has announced advancements in five studies investigating DehydraTECHTM CBD as a treatment for hypertension. This includes three human clinical trials and two animal studies. The studies aim to evaluate CBD's absorption rates and its potential effects on blood pressure. Initial results from animal studies are expected by May, while human trial findings are anticipated by September. Lexaria, holding 18 international patents, aims to leverage these studies for potential commercial opportunities in the $28 billion annual hypertension market.
FAQ
What is the current stock price of Lexaria Bioscien (LEXXW)?
